Search

Displaying results 3511 - 3520 of 6835 in total
  1. Drug

    Protirelin

    go.drugbank.com/drugs/DB09421
    Approved

    It is a tri-peptide tropic hormone, released by the hypothalamus, that stimulates the release of Thyroid Stimulating Hormone (TSH) and prolactin from the anterior pituitary. … Although not currently available in any FDA-approved product, protirelin is a component of the TRH Test where it is used to test the response of the anterior pituitary gland in conditions such as secondary

  2. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to … [A193014] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.

  3. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).

  4. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

  5. Drug

    Stanozolol

    go.drugbank.com/drugs/DB06718
    ApprovedVet approved

    Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.

  6. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  7. Drug

    Bacillus calmette-guerin substrain connaught live antigen

    go.drugbank.com/drugs/DB10804
    ApprovedInvestigationalWithdrawn

    and/or T1 papillary tumors following transurethral resection (TUR). … substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta

  8. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people. … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

  9. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  10. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_. … The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001].